Human tumor antigens recognized by T cells.
The ability of tumor-reactive T cells to mediate in vivo tumor regression has been demonstrated in murine tumor models and by the clinical responses to adoptive immunotherapy with tumor-infiltrating lymphocytes isolated from human melanomas. Investigations carried out in the past several years have resulted in the isolation of a number of the genes encoding antigens recognized by melanoma-reactive T cells. The ability of these products to serve as tumor regression antigens has now begun to be evaluated in clinical vaccine trials.
Surgery Branch, National Institutes of Health, National Cancer Institute, Bethesda, MD 20892-1502, USA. pfr@helix.nih.gov
P F
PF
Robbins
Y
Y
Kawakami
D000595:Amino Acid Sequence; D000818:Animals; D000951:Antigens, Neoplasm / Q000235:genetics; D019496:Cancer Vaccines / Q000494:pharmacology; D002986:Clinical Trials as Topic; D000939:Epitopes / Q000235:genetics; D006801:Humans; D007108:Immune Tolerance; D008545:Melanoma / Q000235:genetics / Q000276:immunology / Q000628:therapy; D051379:Mice; D008969:Molecular Sequence Data; D009154:Mutation; D013601:T-Lymphocytes / Q000276:immunology*
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D000939:Epitopes